VBS.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 00:01):

Stats
Today's Volume	2 000.00
Average Volume	7 304.00
Market Cap	14.63M
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.87
ATR14	$0 (0.00%)

Vectus Biosystems Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vectus Biosystems Limited Financials

Annual	2023
Revenue:	$1.35M
Gross Profit:	$1.31M (96.51 %)
EPS:	$-0.0719

Q2	2024
Revenue:	$648 175
Gross Profit:	$619 427 (95.56 %)
EPS:	$-0.0222

Q4	2023
Revenue:	$775 265
Gross Profit:	$750 295 (96.78 %)
EPS:	$-0.0246

Q3	2022
Revenue:	$387 633
Gross Profit:	$387 633 (100.00 %)
EPS:	$-0.0123

Financial Reports:

No articles found.

Vectus Biosystems Limited

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.